特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
市場調査レポート
商品コード
926209

プロマクタ/レボレード(エルトロンボパグ):医薬品の分析と2030年までの市場予測

Promacta/Revolade (eltrombopag) - Drug Insight and Market Forecast - 2030

出版日: | 発行: DelveInsight Business Research LLP | ページ情報: 英文 | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=105.49円
プロマクタ/レボレード(エルトロンボパグ):医薬品の分析と2030年までの市場予測
出版日: 2020年02月01日
発行: DelveInsight Business Research LLP
ページ情報: 英文
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートでは、主要7カ国 (米国、英国、ドイツ、フランス、イタリア、スペイン、日本)のプロマクタ/レボレード(エルトロンボパグ)市場を調査し、薬品概要、開発動向、特許情報、売上の推移と予測、臨床試験の動向、競合情勢などについてまとめています。

第1章 製品概要

  • 適応症
  • 作用機序
  • 用法・用量
  • 合成経路
  • 薬理学
  • 副作用
  • 製品のスナップショット
  • プロマクタ/レボレード(エルトロンボパグ)の開発マイルストーン
  • 上市の詳細
    • 米国
    • 欧州
    • 日本
  • 特許の詳細

第2章 SWOT分析

  • アナリストの視点

第3章 規制のマイルストーン

  • 承認
  • 研究開発
  • 臨床試験情報
  • 安全性と有効性
  • 製品開発活動

第4章 市場評価

  • 主要7カ国市場の分析
  • 米国
  • 欧州(英国・ドイツ・フランス・イタリア・スペイン)
  • 日本
  • 主な調査結果

第5章 競合情勢

第6章 新たな治療法

第7章 付録

図表

List of Tables

  • Table 1 Promacta/Revolade (eltrombopag) , Description
  • Table 2 Promacta/Revolade (eltrombopag) , Trial Diversification
  • Table 3 Promacta/Revolade (eltrombopag) , Marketed Details United States
  • Table 4 Promacta/Revolade (eltrombopag) , Marketed Details Europe
  • Table 5 Promacta/Revolade (eltrombopag) , Marketed Details Japan
  • Table 6 Patent Details: Promacta/Revolade (eltrombopag)
  • Table 7 Promacta/Revolade (eltrombopag) , Clinical Trial Description, 2020
  • Table 8 Safety and Efficacy Results for Promacta/Revolade (eltrombopag)
  • Table 9 Promacta/Revolade (eltrombopag) , 7MM Market Size from 2017 to 2030 (in Million USD)
  • Table 10 Promacta/Revolade (eltrombopag) , US Market Size from 2017 to 2030 (in Million USD)
  • Table 11 Promacta/Revolade (eltrombopag) , EU Market Size from 2017 to 2030 (in Million USD)
  • Table 12 Promacta/Revolade (eltrombopag) , EU5 Market Size from 2017 to 2030 (in Millions USD)
  • Table 13 Promacta/Revolade (eltrombopag) , Japan Market Size from 2017 to 2030 (in Million USD)
  • Table 14 Market Competitors
  • Table 15 Emerging Therapies

List of Figures

  • Figure 1 The Development Timeline of Promacta/Revolade (eltrombopag)
  • Figure 2 Patent Details, Promacta/Revolade (eltrombopag)
  • Figure 3 Promacta/Revolade (eltrombopag) , 7MM Market Size from 2017 to 2030 (in Million USD)
  • Figure 4 Promacta/Revolade (eltrombopag) , US Market Size from 2017 to 2030 (in Millions USD)
  • Figure 5 Promacta/Revolade (eltrombopag) , EU Market Size from 2017 to 2030 (in Millions USD)
  • Figure 6 Promacta/Revolade (eltrombopag) , EU5 Market Size from 2017 to 2030 (in Millions USD)
  • Figure 7 Promacta/Revolade (eltrombopag) , Japan Market Size from 2017 to 2030 (in Millions USD)
目次
Product Code: DIDM0018

Overview

"Promacta/Revolade (eltrombopag) - Drug Insight and Market Forecast - 2030" report by DelveInsight outlays comprehensive insights of the product indicated for the treatment of its approved condition. A detailed picture of the Promacta/Revolade (eltrombopag) in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2017-2030 is provided in this report along with a detailed description of the product. The product details covers mechanism of action, dosage and administration, route of synthesis, and pharmacological studies, including product marketed details, regulatory milestones, and other development activities. Further, it also consists of market assessments inclusive of the market forecast, SWOT analysis, and detailed analyst views. It further highlights the market competitors, late-stage emerging therapies, and patent details in the global space.

Scope of the report

The report provides insights into:

  • A comprehensive product overview including the product description, mechanism of action, dosage and administration, route of synthesis, pharmacological studies (pharmacodynamics and pharmacokinetics) and adverse reactions.
  • Elaborated details on regulatory milestones and other development activities have been provided in this report.
  • The report also highlights the drug marketed details across the United States, Europe and Japan.
  • The report also covers the patents information with expiry timeline around Promacta/Revolade (eltrombopag) .
  • The report contains historical and forecasted sales for Promacta/Revolade (eltrombopag) till 2030.
  • Comprehensive coverage of the late-stage emerging therapies (Phase III) in the space with a brief snapshot of the details.
  • The report also features the SWOT analysis with analyst insights and key findings of Promacta/Revolade (eltrombopag) .

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Promacta/Revolade (eltrombopag) Analytical Perspective by DelveInsight

  • In-depth Promacta/Revolade (eltrombopag) Market Assessment

This report provides a detailed market assessment of Promacta/Revolade (eltrombopag) in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides historical and forecasted sales data from 2017 to 2030.

  • Promacta/Revolade (eltrombopag) Clinical Assessment

The report provides the clinical trials information of Promacta/Revolade (eltrombopag) covering trial interventions, trial conditions, trial status, start and completion dates.

Report highlights

  • In the coming years, the market scenario for Promacta/Revolade (eltrombopag) is set to change due to the extensive research in the treatment of the indicated condition and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Promacta/Revolade (eltrombopag) dominance. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Other approved products for the disease are giving market competition to Promacta/Revolade (eltrombopag) and launch of late-stage emerging therapies in the near future will significantly impact the market.
  • A detailed description of regulatory milestones, development activities, and some key findings provide the current market scenario of Promacta/Revolade (eltrombopag) .
  • Our in-depth analysis of the sales data of Promacta/Revolade (eltrombopag) from 2017 to 2030 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the Promacta/Revolade (eltrombopag) in the market.

Key Questions

  • What is the prescribed dosage and strengths of Promacta/Revolade (eltrombopag) are available in the market?
  • What are the common adverse reactions or side effects of Promacta/Revolade (eltrombopag) ?
  • What is the product type, route of administration and mechanism of action of Promacta/Revolade (eltrombopag) ?
  • What are the chemical specifications of Promacta/Revolade (eltrombopag) ?
  • How are the clinical trials diversified on the basis of the trial status?
  • What is the history of Promacta/Revolade (eltrombopag) , and what is its future?
  • What are the marketed details of Promacta/Revolade (eltrombopag) in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
  • How many patents have been granted to Promacta/Revolade (eltrombopag) and when these patents will get expire?
  • What are the pros (benefits) and cons (disadvantages) of Promacta/Revolade (eltrombopag) ?
  • In which countries Promacta/Revolade (eltrombopag) got approval and when it gets launched?
  • What are the clinical trials are currently ongoing for Promacta/Revolade (eltrombopag) ?
  • How the safety and efficacy results determined the approval of Promacta/Revolade (eltrombopag) ?
  • What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Promacta/Revolade (eltrombopag) development?
  • What are the key designations that have been granted to Promacta/Revolade (eltrombopag) ?
  • What is the historical and forecasted market scenario of Promacta/Revolade (eltrombopag) ?
  • How is the market trend of Promacta/Revolade (eltrombopag) is different in the Seven Major Markets (the United States, EU5 [Germany, France, Italy, Spain, and the United Kingdom], and Japan)?
  • What are the other approved products available and how these are giving competition to Promacta/Revolade (eltrombopag) ?
  • Which are the late-stage emerging therapies under development for the treatment of the indicated condition?

Table of Contents

1. Product Overview

  • 1.1. Indication
  • 1.2. Mechanism of Action
  • 1.3. Dosage and Administration
    • 1.4.1 Dosage Forms and Strengths
  • 1.4. Route of Synthesis
  • 1.5. Pharmacology
    • 1.4.2 Pharmacodynamics
    • 1.4.3 Pharmacokinetics
  • 1.6. Adverse Reactions
  • 1.7. Product Snapshot
  • 1.8. Development Milestones of Promacta/Revolade (eltrombopag)
  • 1.9. Marketed Details
    • 1.4.4 United States
    • 1.4.5 Europe
    • 1.4.6 Japan
  • 1.10. Patent Details

2. SWOT Analysis

  • 2.1. Analyst Views

3. Regulatory Milestones

  • 3.1. Approvals
  • 3.2. Research and Development
  • 3.3. Clinical Trials Information
  • 3.4. Safety and Efficacy
  • 3.5. Product Developmental Activities

4. Market Assessment

  • 4.1. 7MM Market Analysis
  • 4.2. United States
  • 4.3. Europe
  • 4.4. Japan
  • 4.5. Key Findings

5. Market Competitors

6. Emerging Therapies

7. Appendix

  • 7.1. Report Purchase Options
株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.